Expert Opinion on Investigational Drugs, volume 17, issue 4, pages 547-553

OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review

Gerber M., Ackermann G.
Publication typeJournal Article
Publication date2008-03-25
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor6.1
ISSN13543784, 17447658
Abstract
Background: Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and more severe clinical cases initiated the search for new treatment options. Objective: OPT-80, also known as tiacumicin B, lipiarmycin or PAR-101, is a macrocyclic antimicrobial with little or no systemic absorption after oral administration and narrow activity spectrum against Gram-positive aerobic and anaerobic bacteria. Methods: Data on OPT-80 available from published studies, presentations at conferences and the manufacturer were collected and reviewed. Results/conclusion: The in vitro studies of OPT-80 and clinical C. difficile strains showed high activity at low concentrations. Safety and efficacy of the drug were found to be favourable. More Phase II and III clinical trials are to be completed.

Citations by journals

1
2
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology, 2, 5.13%
Therapeutic Advances in Gastroenterology
2 publications, 5.13%
World Journal of Emergency Surgery
World Journal of Emergency Surgery, 2, 5.13%
World Journal of Emergency Surgery
2 publications, 5.13%
Mayo Clinic Proceedings
Mayo Clinic Proceedings, 2, 5.13%
Mayo Clinic Proceedings
2 publications, 5.13%
Natural Product Reports
Natural Product Reports, 2, 5.13%
Natural Product Reports
2 publications, 5.13%
Expert Review of Anti-Infective Therapy
Expert Review of Anti-Infective Therapy, 2, 5.13%
Expert Review of Anti-Infective Therapy
2 publications, 5.13%
Molecular Diversity
Molecular Diversity, 1, 2.56%
Molecular Diversity
1 publication, 2.56%
Current Opinion in Infectious Diseases
Current Opinion in Infectious Diseases, 1, 2.56%
Current Opinion in Infectious Diseases
1 publication, 2.56%
World Journal of Gastroenterology
World Journal of Gastroenterology, 1, 2.56%
World Journal of Gastroenterology
1 publication, 2.56%
Annals of Pharmacotherapy
Annals of Pharmacotherapy, 1, 2.56%
Annals of Pharmacotherapy
1 publication, 2.56%
Molecules
Molecules, 1, 2.56%
Molecules
1 publication, 2.56%
Communications Chemistry
Communications Chemistry, 1, 2.56%
Communications Chemistry
1 publication, 2.56%
Nature
Nature, 1, 2.56%
Nature
1 publication, 2.56%
Indian Journal of Gastroenterology
Indian Journal of Gastroenterology, 1, 2.56%
Indian Journal of Gastroenterology
1 publication, 2.56%
Current Emergency and Hospital Medicine Reports
Current Emergency and Hospital Medicine Reports, 1, 2.56%
Current Emergency and Hospital Medicine Reports
1 publication, 2.56%
Drugs
Drugs, 1, 2.56%
Drugs
1 publication, 2.56%
Current Opinion in Microbiology
Current Opinion in Microbiology, 1, 2.56%
Current Opinion in Microbiology
1 publication, 2.56%
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 1, 2.56%
European Journal of Medicinal Chemistry
1 publication, 2.56%
International Journal of Infectious Diseases
International Journal of Infectious Diseases, 1, 2.56%
International Journal of Infectious Diseases
1 publication, 2.56%
Critical Care Clinics
Critical Care Clinics, 1, 2.56%
Critical Care Clinics
1 publication, 2.56%
Gastroenterology Clinics of North America
Gastroenterology Clinics of North America, 1, 2.56%
Gastroenterology Clinics of North America
1 publication, 2.56%
Israel Journal of Chemistry
Israel Journal of Chemistry, 1, 2.56%
Israel Journal of Chemistry
1 publication, 2.56%
Journal of the American Chemical Society
Journal of the American Chemical Society, 1, 2.56%
Journal of the American Chemical Society
1 publication, 2.56%
Expert Review of Gastroenterology and Hepatology
Expert Review of Gastroenterology and Hepatology, 1, 2.56%
Expert Review of Gastroenterology and Hepatology
1 publication, 2.56%
Expert Opinion on Emerging Drugs
Expert Opinion on Emerging Drugs, 1, 2.56%
Expert Opinion on Emerging Drugs
1 publication, 2.56%
Expert Opinion on Pharmacotherapy
Expert Opinion on Pharmacotherapy, 1, 2.56%
Expert Opinion on Pharmacotherapy
1 publication, 2.56%
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 1, 2.56%
Journal of Antimicrobial Chemotherapy
1 publication, 2.56%
Expert Opinion on Drug Discovery
Expert Opinion on Drug Discovery, 1, 2.56%
Expert Opinion on Drug Discovery
1 publication, 2.56%
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, 1, 2.56%
Antimicrobial Agents and Chemotherapy
1 publication, 2.56%
1
2

Citations by publishers

1
2
3
4
5
6
7
8
Springer Nature
Springer Nature, 8, 20.51%
Springer Nature
8 publications, 20.51%
Elsevier
Elsevier, 7, 17.95%
Elsevier
7 publications, 17.95%
Taylor & Francis
Taylor & Francis, 6, 15.38%
Taylor & Francis
6 publications, 15.38%
SAGE
SAGE, 3, 7.69%
SAGE
3 publications, 7.69%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 2, 5.13%
Royal Society of Chemistry (RSC)
2 publications, 5.13%
Wolters Kluwer Health
Wolters Kluwer Health, 1, 2.56%
Wolters Kluwer Health
1 publication, 2.56%
Baishideng Publishing Group
Baishideng Publishing Group, 1, 2.56%
Baishideng Publishing Group
1 publication, 2.56%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 1, 2.56%
Multidisciplinary Digital Publishing Institute (MDPI)
1 publication, 2.56%
Wiley
Wiley, 1, 2.56%
Wiley
1 publication, 2.56%
American Chemical Society (ACS)
American Chemical Society (ACS), 1, 2.56%
American Chemical Society (ACS)
1 publication, 2.56%
Oxford University Press
Oxford University Press, 1, 2.56%
Oxford University Press
1 publication, 2.56%
American Society for Microbiology
American Society for Microbiology, 1, 2.56%
American Society for Microbiology
1 publication, 2.56%
1
2
3
4
5
6
7
8
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Gerber M., Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review // Expert Opinion on Investigational Drugs. 2008. Vol. 17. No. 4. pp. 547-553.
GOST all authors (up to 50) Copy
Gerber M., Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review // Expert Opinion on Investigational Drugs. 2008. Vol. 17. No. 4. pp. 547-553.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1517/13543784.17.4.547
UR - https://doi.org/10.1517%2F13543784.17.4.547
TI - OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review
T2 - Expert Opinion on Investigational Drugs
AU - Gerber, M
AU - Ackermann, G
PY - 2008
DA - 2008/03/25 00:00:00
PB - Taylor & Francis
SP - 547-553
IS - 4
VL - 17
SN - 1354-3784
SN - 1744-7658
ER -
BibTex
Cite this
BibTex Copy
@article{2008
author = {M Gerber and G Ackermann},
title = {OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review},
journal = {Expert Opinion on Investigational Drugs},
year = {2008},
volume = {17},
publisher = {Taylor & Francis},
month = {mar},
url = {https://doi.org/10.1517%2F13543784.17.4.547},
number = {4},
pages = {547--553},
doi = {10.1517/13543784.17.4.547}
}
Found error?